ANI Pharmaceuticals Inc. has reached an agreement to acquire Alimera Sciences Inc. for a total consideration of approximately $381 million. This transformative transaction has been approved by the boards of both companies and is anticipated to close by the end of Q3 2024. Alimera, a global pharmaceutical company focused on eye-related conditions, brings two key products to the table: ILUVIEN and YUTIQ. ANI’s CEO, Nikhil Lalwani, emphasizes that this acquisition aligns with ANI’s strategic focus on expanding its Rare Disease business and ophthalmology capabilities. The acquisition is expected to enhance shareholder value through substantial accretion in adjusted Non-GAAP EPS starting from 2025. Alimera’s CEO, Rick Eiswirth, also expressed satisfaction with the deal, noting that it offers compelling value for Alimera’s shareholders and aligns with both companies’ mission of prioritizing patient needs.

Pharmaceuticals, Healthcare,United States, Europe, Middle East